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Abstract
A strain-release-driven, cation-templated nucleophilic 7- and 8-exotrig-cyclization of tethered 
Boc-protected amines to cyclopropenes is described. The featured reaction proceeds in diastereo- 
and regioselective fashion and allows for preparation of the corresponding 2,5-
diazabicyclo[5.1.0]octan-6-ones and 2,6-diazabicyclo[6.1.0]nonan-7-ones as sole products in high 
yields. Preliminary studies on anticancer activities of these novel cyclopropane-fused medium 
heterocycles were performed.
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The cyclopropene double bond is characterized by enhanced strain energy and much greater 
electrophilicity as compared to normal olefins. This feature allows for the utilization of 
strain-release driven addition of various nucleophilic entities across the C=C bond of 
cyclopropenes in design of bio-orthogonal transformations1 or for the development of 
synthetic strategies toward novel cyclopropyl scaffolds.2 Employment of carbon-,3 nitrogen-,
4 oxygen-,5 sulfur-,6 or halogen-based7 nucleophiles has been demonstrated in the 
intermolecular mode of the ring-retentive addition (Scheme 1, eq 1). The intramolecular 
version of this reaction involving nucleophilic species tethered to cyclopropenes and leading 
to the formation of fused bicyclic ring systems is much more challenging. Synthetic 
methodology employing 5-exo-trig nucleophilic attack by stabilized carbanions 3 allowing 
access to bicyclic lactams 4 (Scheme 1, eq 2) was recently developed in our group.8 We also 
demonstrated several modes of potassium-templated cyclizations involving nucleophilic 
alkoxides 5 that afford medium sized cyclic ethers 6 (Scheme 1, eq 3).9 During these studies, 
novel scaffolds were identified possessing promising biological activity,9a which justified 
further synthetic efforts, especially toward medium sized cyclic amines 8, that could mimic 
β- or γ-turns of polypeptides. Herein, we wish to disclose our initial progress toward this 
goal.
RESULTS AND DISCUSSION
At first glance, the planned cyclization involving amine-based nucleophilic entities seemed 
to be a reasonably straightforward extension of the work previously performed with 
alkoxides but, as usual, the devil was in the details. It should be pointed out that for 
successful base-assisted addition of the heteroatom-based entities across C=C bond of 
cyclopropenes, fine balance between nucleophilicity and acidity must be maintained.4,5 
Thus, the ring-retentive reaction of cyclopropenes with primary amines (9, X = NH2, 
NHAlk) cannot be achieved because the nucleophilicity of these neutral amines is much 
lower that of alkoxides, and their acidity is not sufficient to produce much more reactive 
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anionic entities in the presence of typically employed weak bases. Increasing the strength of 
the base proved counterproductive because concurrent deprotonation of acidic C−H bonds of 
cyclopropene occurs, greatly diminishing its electrophilicity. At higher temperature, it was 
possible to force a thermally induced intramolecular nucleophilic attack in substrate 9, but 
the resulting donor−acceptor cyclopropane 10 tended toward facile ring-cleavage10,11 and 
subsequent decomposition of cyclic imine 11 (Scheme 2).12
Arguably, the best solution to this problem would be the employment of an appropriate 
protecting group at the amine function, acidifying the N−H bond in the precursor and 
moderating the electron-donating character of the nitrogen atom in the cyclic product. Given 
the availability of the corresponding starting materials for this preliminary communication, 
we decided to concentrate on reactivity of Boc-protected amines 7. To this end, 1-
phenylcycloprop-2-ene-1-carboxylic acid 12a was subjected to the acylation reaction with 
tert-butyl (2-aminoethyl)carbamate 13a. Without purification, the resulting amide 7aa was 
treated with powdered KOH to afford the desired 2,5-diazabicyclo[5.1.0]octan-6-one 8aa as 
the sole product in 86% overall yield (Scheme 3, entry1). This reaction proved to be pretty 
general for 7-exo-trig cyclization showing high tolerance for substituents at the amide 
nitrogen and at the C-1 of cyclopropene. It was shown that the starting amines could be 
protected not only by benzyl or substituted benzyl groups but also by alkyl (entries 4, 5, 9, 
13−15, and 17) or 2-picolyl moieties (entry 6). The aryl group at quaternary center of 
cyclopropene (C-1) can bear alkoxy (12b) or halogen substituents (12c−f). All seven-
membered bicyclic amides were obtained in very high yields as sole products (Scheme 3).
Similarly, acylation of cyclopropene-3-carboxylic acids 12a, e, and f with N-benzylated 
derivatives of (3-aminopropyl)-carbamate 13h−j afforded the corresponding tethered 
carbamates 7 in crude form (Scheme 4). After treatment with a base, the latter underwent 
smooth 8-exo-trig cyclization, leading to the formation of 2,6-diazabicyclo[6.1.0]nonan-7-
ones 8ah, 8eh, 8ej, and 8fh (Scheme 4, entries 18−21). Next, we investigated if the 
diastereoselectivity of this reaction could be affected by the presence of additional 
stereogenic centers. First, we employed chiral cycloprop-2-enecarboxylic acids 12g and h 
(in racemic form, Scheme 5). They were converted into monocarbamates 13h and j 
uneventfully, and the following base-assisted cyclizations afforded tertiary amide species 7, 
possessing chiral cyclopropene units (Scheme 5). We were pleased to find that the reaction 
of these precursors proceeded regio- and diastereoselectively, affording in high yields seven-
(8ga, 8ha, and 8hb) and eight-membered (8gh and 8hi) heterocycles as sole products with 
relative configurations (1S*,7S*,8R*) and (1S*,8S*,9R*), respectively (Scheme 5, entries 
22−26). Overall, the addition of N−H moiety across C==C bond of cyclopropene proceeded 
in a formal syn-fashion. Next, reaction of tethered carbamate 7ck assembled by acylation of 
L-valine-derived chiral amine 13k with prochiral cycloprop-2-enecarboxylic acid 12c was 
evaluated (Scheme 6).
Cyclopropene moiety in 7ck possesses two diastereotopic sites for nucleophilic attack, but 
only one of them is involved in the reaction, giving rise to product 8ck with (1S,4S,7S)-
configuration and bulky isopropyl group in the more favored bowsprit configuration (as 
shown by X-ray crystallography, see Figure 1). This stereochemical outcome is very similar 
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to the one recently reported for assembly of cyclopropane-fused oxazepanones (6, n = 1) via 
7-exo-trig cyclizations of tethered chiral alkoxides.9a
As mentioned above, the obtained structures constitute very attractive biological probes as 
this unique heterocyclic scaffold just recently emerged on the chemical space map.13 
Accordingly, we performed a preliminary biological evaluation of a few representative 
compounds for anticancer activity using HeLa cell line (ATCC CCL-2) as a model for 
human cervical adenocarcinoma (Table 1) through the measurements of mitochondrial 
dehydrogenase activities using the MTT method.14 Our preliminary tests revealed that some 
of obtained compounds possess strong anticancer activity, and the level of biological activity 
is very dependent on the character of R1 and R2 substituents in designed structures (Scheme 
2). For example, the changing of R2 from aryl or benzyl groups to alkyl group eliminates the 
antiproliferative activity of synthesized compounds 8 completely. The same effect was 
observed as a result of the replacement of H with Ph at the CH2-group of the cyclopropane 
ring. At the same time, significant improvement of biological activity (almost threefold) was 
achieved after incorporation of Br in the meta-position of the aryl ring at C-1 (R1 
substituent). Thus, the obtained compounds 8ec and 8ej revealed great promise as novel 
anticancer scaffolds and will be the subject of further investigations.
CONCLUSION
In conclusion, a novel and highly efficient cyclization involving alkali-metal templated ring-
retentive exo-trig nucleophilic attack of tethered amine moiety (activated by carbamate 
group) at the cyclopropene double bond was demonstrated. It was shown that this reaction 
proceeds in a highly regio- and diastereoselective fashion, which allows access to previously 
unknown cyclopropane-fused medium-sized nitrogen-based heterocycles as sole products. 
Utilization of chiral diamines derived from natural amino acids allows for expeditious access 
to enantiomerically pure molecules. Preliminary evaluation of the bioactivity of these 
previously unknown drug-like scaffolds was performed to reveal several structures with 
promising anticancer properties. Further synthetic studies utilizing a variety of different 
activating groups and building a library for further SAR-investigations are currently 
underway in our laboratories.
EXPERIMENTAL SECTION
General.
NMR spectra were recorded on a Bruker Avance DRX-500 (500 MHz) with a dual carbon/
proton cryoprobe (CPDUL). 13C NMR spectra were registered with broadband decoupling. 
The (+) and (−) designations represent positive and negative intensities of signals in 13C 
DEPT-135 experiments. IR spectra were recorded on a ThermoFisher Nicolet iS 5 FT-IR 
Spectrometer. HRMS was carried out on LCT Premier (Micromass Technologies) 
instrument employing ESI TOF detection techniques. Glassware used in moisture-free 
syntheses was flame-dried in vacuum prior to use. Column chromatography was carried out 
on silica gel (Sorbent Technologies, 40−63 mm). Precoated silica gel plates (Sorbent 
Technologies Silica XG 200 mm) were used for TLC analyses. Anhydrous dichloro-methane 
was obtained by passing degassed commercially available HPLC-grade inhibitor-free solvent 
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consecutively through two columns filled with activated alumina and stored over molecular 
sieves under nitrogen. Water was purified by dual stage deionization followed by dual stage 
reverse osmosis. Anhydrous THF was obtained by refluxing commercially available solvent 
over calcium hydride followed by distillation in a stream of dry nitrogen. All other reagents 
and solvents were purchased from commercial vendors and used as received.
Biological Studies.
Cell culture: HeLa cells were cultured in DMEM supplemented with 10% FBS. To evaluate 
antiproliferative properties of the synthesized compounds, the cells were trypsinized and 
seeded 4 × 103 cells per well into 96-well microtiter plates. The cells were grown for 24 h 
before treatment.
MTT assay for HeLa: All compounds were dissolved in DMSO at a concentration of either 
100 or 50 mM prior to cell treatment. The cells were treated at concentrations ranging from 
0.004 to 100 μM and incubated for 48 h in 200 μL of media. Twenty microliters of MTT 
reagent in serum-free medium (5 mg/mL) was added to each well and incubated further for 2 
h. Media was removed, and the resulting formazan crystals were resolubilized in 100 μL of 
DMSO. A490 was measured using a Thermomax Molecular Device plate reader. The 
experiments were performed in quadruplicate and repeated at least twice for each compound 
per cell line. Cells treated with 0.1% DMSO were used as a negative control, and phenyl 
arsine oxide (PAO) was used as a positive killing control.
Preparation of Starting Materials.
1-(4-Methoxyphenyl)-cycloprop-2-ene-1-carboxylic Acid (12b).—Typical 
procedure: Methyl (4-methoxyphenyl)acetate (6.86 g, 41.3 mmol, 1.00 equiv), and tosyl 
azide (9.0 g, 45.4 mmol, 1.1 equiv) were stirred in acetonitrile (150 mL) at 0 °C, and DBU 
(7.54 g, 49.5 mmol, 1.2 equiv) was added dropwise. Upon complete addition, the reaction 
was warmed to room temperature and stirred overnight. The solvent was then removed in 
vacuum, and the residue was partitioned between saturated ammonium chloride (100 mL) 
and methylene chloride (75 mL). The aqueous phase was then extracted with methylene 
chloride (3 × 30 mL). Combined organic phases were then washed with brine, dried with 
MgSO4, filtered, and concentrated. The recovered material was then filtered through a short 
pad of silica gel (15 g) as solution in hexanes. The filtrate was concentrated in vacuum to 
obtain crude methyl 2-diazo-2-(4-methoxyphenyl)acetate as a red oil. This material was then 
mixed with trimethylsilylacetylene (2 mL) and added via a syringe pump over 18 h to a 
stirring and refluxing suspension of rhodium(II) acetate dimer (27.4 mg, 0.124 mmol, 0.3 
mol %) in trimethylsilylacetylene (47 mL, 413 mmol, 10.0 equiv). The reaction was 
monitored by gas chromatography until complete consumption of the starting material was 
observed. Then, the reflux condenser was replaced with a distilling head, and most of the 
trimethylsilylacetylene was recovered by distillation at ambient pressure. The residual 
solvent was then removed under vacuum. The reaction mixture was then purified by short 
column chromatography, eluting with a mixture of hexane:EtOAc (10:1). Crude ethyl 1-(4-
methoxyphenyl)-2-(trimethylsilyl)cycloprop-2-ene-1-carboxylate was obtained as a 
yellowish oil, which was stirred at 0 °C in a mixture of methanol and THF (1:1, 200 mL). 
An aqueous solution of sodium hydroxide (2 M, 200 mL) was added dropwise, and the 
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mixture was stirred for 18h. Organic solvents were then removed under vacuum, and the 
remaining aqueous solution was washed with dichloromethane (3 × 50 mL). The mixture 
was acidified to pH 2 with 2 M aqueous HCl and extracted with dichloromethane (3 × 50 
mL). The combined organic phases were washed with brine, dried with MgSO4, filtered, and 
concentrated. The obtained product was purified by column chromatography on silica gel 
eluting with a mixture of hexane:EtOAc (2:1). The title compound was obtained as an off-
white crystalline solid (Rf 0.3, mp 115−116 °C). Overall yield 2.198 g (11.6 mmol, 28%). 
1H NMR (500 MHz, CDCl3) δ 7.22 (s, 2H), 7.24−7.19 (m, 2H), 6.87−6.81 (m, 2H), 3.79 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 180.7, 158.5, 132.9, 129.5 (+, 2C), 113.8 (+, 2C), 
107.6 (+, 2C),55.4 (+), 29.7. FT IR (NaCl, cm−1): 3440 (br.), 1689, 1659, 1514, 1246, 1030, 
773. HRMS (ESI-TOF) m/z: [M − H]− Calcd for C11H9O3 189.0552; Found 189.0551 (0.5 
ppm).
1-(3-Chlorophenyl)cycloprop-2-ene-1-carboxylic Acid (12d).—This compound was 
obtained from methyl (3-chlorophenyl)acetate(5.65 g, 33.1 mmol) using the protocol 
described for the synthesis of 1-(4-methoxyphenyl)cycloprop-2-ene-1-carboxylic acid (vide 
supra). The title compound was obtained as an off-white crystalline solid (mp 84−86 °C). 
Yield 4.71 g (24.2 mmol, 73%). 1H NMR (500 MHz, CDCl3) δ 7.28 (td, J = 1.8, 0.6 Hz, 
1H), 7.24−7.22 (m, 1H), 7.21 (t, J = 1.9 Hz, 1H), 7.20 (s, 2H), 7.19−7.17 (m, 1H). 13C NMR 
(126 MHz, CDCl3) δ 180.9, 142.7, 134.1, 129.5 (+), 128.7 (+), 127.1 (+), 126.7 (+), 106.8 
(+, 2C), 30.0. FT IR (NaCl, cm−1): 3160 (br.), 1690, 1674, 1595, 1413, 1269, 1091, 984. 
HRMS (ESI-TOF) m/z: [M − H]− Calcd for C10H6ClO2 193.0056; Found 193.0057 (0.5 
ppm).
1-(2,4-Dichlorophenyl)-2-phenylcycloprop-2-ene-1-carboxylic Acid (12h).—This 
compound was obtained using methyl (2,4-dichlorophenyl)acetate (2.11 g, 10.3 mmol) and a 
solution of ethynylbenzene (3.15 g, 30.9 mmol, 3.0 equiv) in 20 mL of CH2Cl2 according to 
the protocol described for the synthesis of 1-(4-methoxyphenyl)cycloprop-2-ene-1-
carboxylic acid (vide supra). The title compound was obtained as a light-beige crystalline 
solid (mp 153−154 °C). Yield 1.79 g (5.87 mmol, 57%). 1H NMR (500 MHz, CDCl3) δ 
7.73−7.68 (m, 2H), 7.50−7.42 (m, 3H), 7.37 (d, J = 2.1 Hz, 1H), 7.31 (s, 1H), 7.23 (d, J = 
8.2 Hz, 1H), 7.11 (dd, J = 8.2, 2.1 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 180.0, 137.9, 
135.9, 133.9, 131.1 (+), 130.6 (+), 130.1 (+, 2C), 129.5 (+), 129.2 (+, 2C), 127.3 (+), 125.2, 
118.1, 101.3 (+), 32.8. FT IR (NaCl, cm−1): 3381 (br.), 1685, 1471, 1260,1101, 821, 698. 
HRMS (ESI-TOF) m/z: [M − H]− Calcd for C16H9Cl2O2 302.9980; Found 302.9982 (0.7 
ppm).
tert-Butyl (S)-(2-(Benzylamino)-3-methylbutyl)carbamate (13k).—A 15 mL 
stainless steel autoclave vessel was charged with tert-butyl (S)-(2-amino-3-
methylbutyl)carbamate15 (300 mg, 1.48 mmol, 1.0 equiv), benzaldehyde (182 μL, 189 mg, 
1.78 mmol, 1.2 equiv), 10 wt % palladium on carbon (78.9 mg, 0.074 mmol, 0.05 equiv), 
and methanol (3 mL). The mixture was stirred under hydrogen gas (1.5 atm) overnight. The 
catalyst was removed by vacuum filtration through Celite 545 nonacid-washed filter aid 
washing with methanol, and then the resulting mixture was evaporated. The product was 
isolated by column chromatography eluting with a chloroform:methanol mixture (40:1) as a 
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colorless oil (Rf 0.24), [α]D20 +1.8° (c 1.50, CHCl3). Yield: 239 mg (0.82 mmol, 55%). 1H 
NMR (400 MHz, CDCl3) δ 7.28−7.15 (m, 5H), 4.97 (br. s, 1H), 3.70 (s, 2H), 3.29−3.12 (m, 
1H), 2.96 (dt, J = 12.9, 6.2 Hz, 1H), 2.36 (q, J = 6.2 Hz, 1H), 1.76 (nonet, J = 6.8 Hz, 1H), 
1.38 (s, 9H), 0.86 (dd, J = 17.1,6.8 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 156.3, 140.6, 
128.5 (+, 2C), 128.2 (+, 2C), 127.0 (+), 79.0, 62.1 (+), 51.5 (−), 40.5 (−),28.5 (+, 3C), 19.2 
(+, 2C), 18.4 (+). FTIR (NaCl, cm−1): 3350 (br.), 2963, 1699,1495, 1366, 1171738, 699. 
HRMS (ESI-TOF) m/z: [M +H]+ Calcd for C17H29N2O2 293.2229, Found 293.2222 (2.4 
ppm).
Synthesis of Medium-Sized Heterocycles.
tert-Butyl (1S*,7S*)-5-Benzyl-6-oxo-7-phenyl-2,5-diazabicyclo[5.1.0]octane-2-
carboxylate (8aa).—Typical procedure: Flame-dried round-bottom flask was charged 
with 1-phenylcycloprop-2-ene-1-carboxylic acid (12a)16 (200 mg, 1.25 mmol, 1.0 equiv), 
DMF (2 drops), and freshly distilled anhydrous dichloromethane (7 mL) under nitrogen 
atmosphere. Oxalyl chloride (400 μL, 592 mg, 4.68 mmol, 1.5 equiv) was then added 
dropwise, and the mixture was stirred at room temperature for 2 h. The solution was 
concentrated in a stream of nitrogen; then, the residue was subjected to a high vacuum, 
dissolved in anhydrous dichloromethane (2.0 mL), and added dropwise to a stirred solution 
of tert-butyl (2-(benzylamino)ethyl)carbamate (13a)17 (375 mg, 1.5 mmol, 1.2 equiv) and 
triethylamine (1.3 mL, 948 mg, 9.36 mmol, 3.0 equiv) in anhydrous dichloromethane (3.0 
mL). The reaction mixture was stirred at room temperature for 18 h and then partitioned 
between water (15 mL) and dichloromethane (20 mL). The aqueous phase was diluted with 
5 mL of concentrated aqueous solution of ammonium chloride. The organic phase was then 
washed with saturated aq NH4Cl (3 × 10 mL). The combined aqueous layers were back-
extracted once with 10 mL of dichloro-methane, which was combined with other organic 
phases, washed with brine, dried with MgSO4, filtered, and concentrated. The crude product 
tert-butyl (2-(N-benzyl-1-phenylcycloprop-2-ene-1-carboxamido)ethyl)carbamate (7aa) was 
filtered through a silica plug using EtOAc and then was concentrated and used at the 
cyclization step as-is without additional purification. An oven-dried 3 mL Wheaton vial was 
charged with powdered KOH (21.4 mg, 0.381 mmol) and anhydrous THF (800 μL). Crude 
carbamate 7aa (60 mg, 0.153 mmol) was added as a solution in anhydrous THF (400 μL). 
The mixture was vigorously stirred at 35 °C for 8 h; then, the reaction mixture was filtered 
through short plug of silica gel eluting with EtOAc, and the eluate was concentrated in 
vacuum. The titled product was isolated by column chromatography eluting with a 
hexanes:EtOAc mixture (3:1) as a colorless solid (Rf 0.30, mp 103−105 °C). Yield: 51.7 mg 
(0.132 mmol, 86%). 1H NMR (500 MHz, C6D6) δ 7.19−7.14 (m, 3H), 7.14−7.06 (m, 5H), 
7.08−7.00 (m, 2H),4.53 (br.s, 1H), 4.29 (br.s, 1H), 3.56 (br.s, 1H), 3.39 (td, J = 13.4, 4.0 Hz, 
1H), 2.54−2.45 (m, 2H), 2.41 (dd, J = 12.8, 3.9 Hz, 1H), 1.97 (t, J = 5.6 Hz, 1H), 1.52 (t, J = 
6.9 Hz, 1H), 1.42 (s, 9H). 13C NMR (126 MHz, C6D6) δ 169.9, 156.5, 139.4, 138.4, 129.0 
(+, 2C), 128.9 (+, 2C), 128.4 (+, 2C), 127.6 (+), 127.0 (+), 125.8 (+, 2C), 79.9,49.6 (−), 44.5 
(−), 43.4 (−), 37.4 (+), 36.4, 28.4 (+, 3C), 26.5 (−). FTIR (NaCl, cm−1): 2975, 2928, 1701, 
1652, 1496, 1470, 1425, 1394, 1366, 1346, 1250, 1146, 1065, 1029, 987, 856, 811, 750, 
698, 632, 606. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 415.1998; Found 415.2008 (2.4 
ppm).
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diazabicyclo[5.1.0]octane-2-carboxylate (8ab).—This compound was synthesized 
according to the typical procedure starting from 1-phenylcycloprop-2-ene-1-carboxylic acid 
(12a)15 (200 mg, 1.25 mmol, 1.0 equiv) and tert-butyl (2-((4-methoxybenzyl)amino)ethyl)-
carbamate (13b)18 (420 mg, 1.5 mmol, 1.2 equiv). After extraction and filtration through a 
silica plug, crude tert-butyl (2-(N-(4-methoxybenzyl)-1-phenylcycloprop-2-ene-1-
carboxamido)ethyl)-carbamate (7ab) was used at the cyclization step as-is without additional 
purification. To this end, amide 7ab (60 mg, 0.142 mmol) was treated with powdered KOH 
(19.9 mg, 0.355 mmol). The reaction mixture was vigorously stirred at 35 °C for 16 h. The 
product was isolated by column chromatography eluting with a hexanes:E-tOAc mixture 
(2:1) as a colorless solid (Rf 0.25, mp 134−136 °C). Yield: 51.7 mg (0.122 mmol, 86%). 1H 
NMR (500 MHz, C6D6) δ7.21−7.17 (m, 2H), 7.11 (dd, J = 8.5, 6.9 Hz, 2H), 7.09−7.05 (m, 
2H), 7.05−6.99 (m, 1H), 6.76−6.69 (m, 2H), 4.50 (br.s, 1H), 4.31 (br.s, 1H), 3.58 (br.s, 1H), 
3.41 (td, J = 13.3, 4.1 Hz, 1H), 3.32 (s, 3H), 2.59−2.51 (m, 1H), 2.48 (dd, J = 7.1, 4.7 Hz, 
1H), 2.43 (dd, J = 12.8, 3.9 Hz, 1H), 1.99 (t, J = 5.6 Hz, 1H), 1.53 (t, J = 6.8 Hz, 1H),1.42 (s, 
9H). 13C NMR (126 MHz, C6D6) δ 169.8, 159.8, 156.5, 139.5, 130.4, 129.8 (+, 2C), 
129.0(+, 2C), 127.0 (+), 125.8 (+, 2C), 114.5 (+, 2C), 79.9, 54.8 (+), 49.1 (−), 44.6 (−), 43.3 
(−), 37.5 (+),36.4, 28.4 (+, 3C), 26.4 (−). FTIR (NaCl, cm−1): 2974, 2923, 1701, 1651, 1513, 
1393, 1248, 1146, 1032, 808, 760. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C25H30N2O4Na 445.2103; Found 445.2104(0.2 ppm).
tert-Butyl(1S*,7S*)-5-(4-Fluorobenzyl)-6-oxo-7-phenyl-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (8ac).—This compound was synthesized 
according to the typical procedure starting from 1-phenylcycloprop-2-ene-1-carboxylic acid 
(12a)15 (200 mg, 1.25 mmol, 1.0 equiv), and tert-butyl (2-((4-fluorobenzyl)amino)ethyl)-
carbamate (13c)19 (402 mg, 1.5 mmol, 1.2 equiv). After extraction and filtration through a 
silica plug, crude tert-butyl (2-(N-(4-fluorobenzyl)-1-phenylcycloprop-2-ene-1-
carboxamido)ethyl)-carbamate (7ac) was used at the cyclization step as-is without additional 
purification. To this end, amide 7ac (60 mg, 0.146 mmol) was treated with powdered KOH 
(20.5 mg, 0.365 mmol). The reaction mixture was vigorously stirred at 35 °C for 16 h. The 
product was isolated by column chromatography eluting with a hexanes:E-tOAc mixture 
(2:1) as a colorless solid (Rf 0.26, mp 112−113 °C). Yield: 53.3 mg (0.13 mmol, 89%). 1H 
NMR (500 MHz, C6D6) δ 7.14 (d, J = 7.4 Hz, 2H), 7.09 (dd, J = 8.5, 6.7 Hz, 2H), 7.05−7.00 
(m, 1H), 6.93 (dd, J = 8.4, 5.5 Hz, 2H), 6.75 (t, J = 8.7 Hz, 2H), 4.34 (br.s, 1H), 4.20 (br.s, 
1H), 3.51 (br.s, 1H), 3.37 (td, J = 13.2, 4.1 Hz, 1H), 2.47 (dd, J = 7.1, 4.6 Hz, 1H), 
2.44−2.37 (m, 2H), 1.95 (t, J = 5.6 Hz, 1H), 1.50 (t, J = 6.9 Hz, 1H), 1.41 (s, 9H). 13C NMR 
(126MHz, C6D6) δ 169.9, 162.8 (d, J = 245.3 Hz), 156.5, 139.2, 134.2 (d, J = 3.5 Hz), 130.1 
(d, J = 8.1 Hz, + , 2C), 129.0 (+, 2C), 127.1 (+), 125.8 (+, 2C), 115.6 (d, J = 21.3 Hz, + , 
2C), 80.0, 48.9 (−), 44.5 (−), 43.5 (−), 37.3 (+), 36.3, 28.4 (+, 3C), 26.4 (−). 19F NMR 
(376MHz, CDCl3) δ −114.6. FTIR (NaCl, cm−1): 2976, 2929, 1701, 1650, 1509, 1365, 
1346, 1222, 1146, 853, 765, 697. HRMS (ESITOF) m/z: [M + Na]+ Calcd for 
C24H27FN2O3Na 433.1903; Found 433.1910 (1.6 ppm).
tert-Butyl(1S*,7S*)-5-Benzyl-7-(3-bromophenyl)-6-oxo-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (8ea).—This compound was synthesized 
Maslivetc et al. Page 8













according to the typical procedure starting from 1-(3-bromophenyl)cycloprop-2-ene-1-
carboxylic acid (12e)5a (200 mg, 0.84 mmol, 1.0 equiv) and tert-butyl (2-
(benzylamino)ethyl)-carbamate (13a)16 (251 mg, 1 mmol, 1.2 equiv). After extraction and 
filtration through a silica plug, crude tert-butyl (2-(N-benzyl-1-(3-bromophenyl)cycloprop-2-
ene-1-carboxamido)ethyl)carbamate (7ea) was used at the cyclization step as-is without 
additional purification. To this end, amide 7ea (60 mg, 0.127 mmol) was treated with 
powdered KOH (17.9 mg, 0.319 mmol). The reaction mixture was vigorously stirred at 
35 °C for 8 h. The product was isolated by column chromatography eluting with a 
hexanes:EtOAc mixture (1:1) as a colorless solid (Rf 0.4, mp 151−152 °C). Yield: 54.6 mg 
(0.116 mmol, 91%). 1H NMR (500 MHz, C6D6) δ 7.38 (t, J = 1.9 Hz, 1H),7.19−7.13 (m, 
2H), 7.13−7.01 (m, 5H), 6.73 (t, J = 7.9 Hz, 1H),4.51 (br.s, 1H), 4.16 (br.s, 1H), 3.51 (br.s, 
1H), 3.20 (td, J = 13.4, 4.1 Hz, 1H), 2.48−2.37 (m, 1H), 2.33 (dd, J = 12.9, 4.0 Hz, 1H), 2.29 
(dd, J = 7.1, 4.7 Hz, 1H), 1.91 (t, J = 5.7 Hz, 1H), 1.41 (s, 9H), 1.39−1.35 (m, 1H). 13C 
NMR (126 MHz, C6D6) δ 169.2, 156.3, 141.9, 138.2, 130.5 (+), 130.2 (+), 128.9 (+, 2C), 
128.7 (+), 128.4 (+, 2C), 127.7 (+), 124.8 (+), 123.4, 80.0, 49.6 (−), 44.3 (−), 43.3 (−), 37.3 
(+), 36.0, 28.4 (+, 3C), 26.6 (−). FTIR (NaCl, cm−1): 2974, 2926, 1702, 1654, 1476, 1393, 
1366, 1344, 1249, 1147, 1062, 994, 777, 754, 697. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd 
for C24H27 79 BrN2O3Na 493.1103; Found 493.1109 (1.2 ppm).
tert-Butyl(1S*,7S*)-7-(3-Bromophenyl)-5-(4-fluorobenzyl)-6-oxo-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (8ec).—This compound was synthesized 
according to the typical procedure starting from 1-(3-bromophenyl)cycloprop-2-ene-1-
carboxylic acid (12e)5 (200 mg, 0.84 mmol, 1.0 equiv) and tert-butyl (2-((4-fluorobenzyl)-
amino)ethyl)carbamate (13c)18 (269 mg, 1 mmol, 1.2 equiv). After extraction and filtration 
through a silica plug, crude tert-butyl (2-(1-(3-bromophenyl)-N-(4-
fluorobenzyl)cycloprop-2-ene-1-carboxamido)ethyl)carbamate (7ec) was used at the 
cyclization step as-is without additional purification. To this end, amide 7ec (60 mg, 0.123 
mmol) was treated with powdered KOH (17.2 mg, 0.307 mmol). The reaction mixture was 
vigorously stirred at 35 °C for 8 h. The product was isolated by column chromatography 
eluting with a hexanes:EtOAc mixture (1:1) as a colorless solid (Rf 0.4, mp 156−157 °C). 
Yield: 54.1 mg (0.111 mmol, 90%). 1H NMR (500 MHz, C6D6) δ 7.35 (t, J = 1.9 Hz, 1H), 
7.19−7.13 (m, 1H), 7.01−6.96 (m, 1H), 6.92 (dd, J = 8.4, 5.5 Hz, 2H), 6.80−6.71 (m, 3H), 
4.31 (br. s, 1H), 4.11 (br. s, 1H), 3.46 (br. s, 1H), 3.20 (ddd, J = 15.4, 13.4, 4.2 Hz, 1H), 
2.42−2.31 (m, 2H), 2.29 (dd, J = 7.1, 4.7 Hz, 1H), 1.88 (dd, J = 6.7, 4.7 Hz, 1H), 1.40 (s, 
9H), 1.43−1.34 (m, 1H). 13C NMR (126 MHz, C6D6) δ 169.2, 162.8 (d, J = 246.0 Hz), 
156.3, 141.8, 134.0 (d, J = 3.4 Hz), 130.5 (+), 130.3 (+), 130.1 (d, J = 8.1 Hz, + , 2C), 128.7 
(+), 124.7 (+), 123.4, 115.7 (d, J = 21.3 Hz, + , 2C), 80.1,48.9 (−), 44.3 (−), 43.4 (−), 37.3 
(+), 35.9, 28.4 (+, 3C), 26.5 (−).19F NMR (376 MHz, C6D6) δ −114.8. FTIR (NaCl, cm−1): 
2977, 2931, 736, 693. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C24H2679BrFN2O3Na 
511.1009; Found 511.1001 (1.6 ppm).
tert-Butyl(1S*,7S*)-5-(4-Methoxybenzyl)-7-(4-methoxyphenyl)-6-oxo-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (8bb).—This compound was synthesized 
according to the typical procedure starting from 1-(4-methoxyphenyl)cycloprop-2-ene-1-
carboxylic acid (12b) (200 mg, 1.05 mmol, 1.0 equiv) and tert-butyl (2-((4-
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methoxybenzyl)amino)ethyl)carbamate (13b)17 (354 mg, 1.26 mmol, 1.2 equiv). After 
extraction and filtration through a silica plug, crude tert-butyl (2-(N-(4-methoxybenzyl)-1-
(4-methoxyphenyl)cycloprop-2-ene-1-carboxamido)ethyl)carbamate (7bb) was used at the 
cyclization step as-is without additional purification. To this end, amide 7bb (60 mg, 0.133 
mmol) was treated with powdered KOH(18.6 mg, 0.332 mmol). The reaction mixture was 
vigorously stirred at 35 °C for 16 h. The product was isolated by column chromatography 
eluting with a hexanes:EtOAc mixture (1:1) as a colorless glass (Rf 0.43). Yield: 55.9 mg 
(0.123 mmol, 93%). 1H NMR (500 MHz, C6D6) δ 7.19−7.16 (m, 2H), 7.07 (d, J = 8.5 Hz, 
2H),6.78−6.70 (m, 4H), 4.57 (br.s, 1H), 4.26 (br.s, 1H), 3.63 (br.s, 1H),3.51 (td, J = 13.4, 3.9 
Hz, 1H), 3.31 (s, 3H), 3.31 (s, 3H), 2.62−2.54 (m, 1H), 2.51−2.46 (m, 2H), 1.97 (t, J = 5.5 
Hz, 1H), 1.51 (t, J = 6.8 Hz, 1H), 1.43 (s, 9H). 13C NMR (126 MHz, C6D6) δ 170.1, 159.7, 
159.3, 156.6, 131.3, 130.4, 129.7 (+, 2C), 127.3 (+, 2C), 114.7 (+, 2C), 114.5 (+, 2C), 79.8, 
54.9 (+), 54.8 (+), 49.0 (−), 44.6 (−), 43.3 (−), 36.9 (+), 36.0, 28.5 (+, 3C), 26.1 (−). FTIR 
(NaCl, cm−1): 2926, 1700, 1649, 1514, 1393, 1248, 1176, 1146, 1032, 829, 784. HRMS 
(ESI-TOF) m/z: [M + Na]+ Calcd for C26H32N2O5Na 475.2209; Found 475.2213 (0.8 ppm).
tert-Butyl (1S*,7S*)-5-Ethyl-6-oxo-7-phenyl-2,5-diazabicyclo- [5.1.0]octane-2-
carboxylate (8ae).—This compound was synthesized according to the typical procedure 
starting from 1-phenylcycloprop-2-ene-1-carboxylic acid (12a)15 (200 mg, 1.25 mmol, 1.0 
equiv), and tert-butyl (2-(ethylamino)ethyl)carbamate (13e)20 (282 mg, 1.5 mmol, 1.2 
equiv). After extraction and filtration through a silica plug, crude tert-butyl (2-(N-ethyl-1-
phenylcycloprop-2-ene-1-carboxamido)ethyl)carbamate (7ae) was used at the cyclization 
step as-is without additional purification. To this end, amide 7ae (60 mg, 0.182 mmol) was 
treated with powdered KOH (25.5 mg, 0.455 mmol). The reaction mixture was vigorously 
stirred at 35 °C for 8 h. The product was isolated by column chromatography eluting with a 
hexanes:EtOAc mixture (2:1) as a colorless glass (Rf 0.43). Yield: 51.1 mg (0.155 mmol, 
85%). 1H NMR (500 MHz, C6D6) δ 7.15−7.07 (m, 4H), 7.04−6.99 (m, 1H), 3.80 (br.t, J = 
10.8 Hz, 1H), 3.42−3.28 (m, 2H), 3.01 (dq, J = 14.1, 7.1 Hz, 1H), 2.56−2.48 (m, 1H), 2.46 
(dd, J = 7.1, 4.6 Hz, 1H), 2.30 (dd, J = 15.2, 4.6 Hz, 1H), 1.92 (t, J = 5.7 Hz, 1H), 1.48 (t, J = 
6.9 Hz, 1H), 1.41 (s, 9H), 0.87 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, C6D6) δ 169.1, 
156.6, 139.6, 128.9 (+, 2C), 126.9 (+), 125.7 (+, 2C), 79.9, 45.0 (−), 43.6 (−), 41.3 (−), 37.7 
(+), 36.5, 28.5 (+, 3C), 26.3 (−), 13.5 (+). FTIR (NaCl, cm−1): 2973, 2926, 1699, 1652, 
1429, 1366, 1346, 1175, 1146, 1065, 757, 697, 614. HRMS (ESI-TOF) m/z: [M + Na]+ 
Calcd for C19H26N2O3Na 353.1841; Found 353.1836, (1.4 ppm).
tert-Butyl(1S*,7S*)-7-(3-Bromophenyl)-5-ethyl-6-oxo-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (8ee).—This compound was synthesized 
according to the typical procedure starting from 1-(3-bromophenyl)cycloprop-2-ene-1-
carboxylic acid (12e)5 (200 mg, 0.84 mmol, 1.0 equiv) and tert-butyl (2-
(ethylamino)ethyl)carbamate (13e)19 (190 mg, 1.0 mmol, 1.2 equiv). After extraction and 
filtration through a silica plug, crude tert-butyl (2-(1-(3-bromophenyl)-N-ethylcycloprop-2-
ene-1-carboxamido)ethyl)carbamate (7ee) was used at the cyclization step as-is without 
additional purification. To this end, amide 7ee (60 mg, 0.147 mmol) was treated with 
powdered KOH (20.6 mg, 0.367 mmol). The reaction mixture was vigorously stirred at 
35 °C for 8 h. The product was isolated by column chromatography eluting with a 
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hexanes:EtOAc mixture (2:1) as a colorless glass (Rf 0.4). Yield: 52.2 mg (0.128 mmol, 
87%). 1H NMR (400 MHz, C6D6) δ 7.30 (t, J = 1.9 Hz, 1H), 7.16−7.11 (m, 1H),7.04 (d, J = 
8.0 Hz, 1H), 6.70 (t, J = 7.9 Hz, 1H), 3.73 (br.s, 1H),3.36−3.20 (m, 1H), 3.16−3.07 (m, 1H), 
2.86 (br.s, 1H), 2.40 (dd, J = 13.0, 4.0 Hz, 1H), 2.23 (dd, J = 7.2, 4.7 Hz, 1H), 2.15 (dd, J = 
15.4,4.5 Hz, 1H), 1.85 (br.s, 1H), 1.39 (s, 9H), 1.42−1.33 (m, 1H), 0.80 (t, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, C6D6) δ 168.5, 156.4, 142.1, 130.5 (+), 130.1 (+), 128.5 (+), 124.9 
(+), 123.3, 80.1, 44.8 (−), 43.5 (−), 41.4 (−), 37.4 (+), 36.2, 28.4 (+, 3C), 26.3, 13.4 (+). 
FTIR (NaCl, cm−1): 2973, 2928, 1701, 1652, 1477, 1394, 1366, 1344, 1249, 1147, 856, 778, 
694. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C19H25BrN2O3Na 431.0946; Found 
431.0953, (1.6 ppm).
tert-Butyl(1S*,7S*)-5-Ethyl-7-(4-fluorophenyl)-6-oxo-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (8ce).—This compound was synthesized 
according to the typical procedure starting from 1-(4-fluorophenyl)cycloprop-2-ene-1-
carboxylic acid (12c)5 (200 mg, 1.12 mmol, 1.0 equiv) and tert-butyl (2-
(ethylamino)ethyl)carbamate (13e)19 (256 mg, 1.35 mmol, 1.2 equiv). After extraction and 
filtration through a silica plug, crude tert-butyl (2-(N-ethyl-1-(4-fluorophenyl)cycloprop-2-
ene-1-carboxamido)ethyl)carbamate (7ce) was used at the cyclization step as-is without 
additional purification. To this end, amide 7ce (60 mg, 0.172 mmol) was treated with 
powdered KOH (24.2 mg, 0.431 mmol). The reaction mixture was vigorously stirred at 
35 °C for 8 h. The product was isolated by column chromatography eluting with a 
hexanes:EtOAc mixture (2:1) as a colorless solid (Rf 0.45, mp 146−148 °C). Yield: 52.2 mg 
(0.15 mmol, 87%). 1H NMR (500 MHz, C6D6) δ 6.98−6.93 (m, 2H),6.78−6.71 (m, 2H), 
3.87−3.72 (m, 1H), 3.34−3.25 (m, 2H), 2.98 (dq, J = 14.1, 7.1 Hz, 1H), 2.53 (dd, J = 13.0, 
4.0 Hz, 1H), 2.35 (dd, J = 7.1, 4.6 Hz, 1H), 2.30 (dd, J = 15.3, 5.0 Hz, 1H), 1.85 (t, J = 5.6 
Hz, 1H), 1.41 (s, 9H), 1.35 (t, J = 6.8 Hz, 1H), 0.84 (t, J = 7.1 Hz, 3H). 13C NMR (126 
MHz, C6D6) δ 169.0, 162.3 (d, J = 246.0 Hz), 156.6, 135.2 (d, J = 3.6 Hz), 127.5 (d, J = 8.1 
Hz, + , 2C), 115.7 (d, J = 21.7 Hz, + , 2C), 80.0, 45.0 (−), 43.5 (−), 41.4 (−), 37.3 (+), 35.9, 
28.5 (+, 3C), 26.1 (−), 13.5 (+). FTIR (NaCl, cm−1): 2975, 2932, 1699, 1651, 1512, 1476, 
1395, 1366, 1345, 1250, 1234, 1148, 1064, 834, 778. 19F NMR (376 MHz, CDCl3) δ 
−115.9. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C19H25FN2O3Na 371.1747; Found 
371.1756(2.4 ppm).
tert-Butyl(1S*,7S*)-7-(3-Bromophenyl)-5-isobutyl-6-oxo-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (8ef).—This compound was synthesized 
according to the typical procedure starting from 1-(3-bromophenyl)cycloprop-2-ene-1-
carboxylic acid (12e)5 (200 mg, 0.84 mmol, 1.0 equiv) and tert-butyl (2-
(isobutylamino)ethyl)-carbamate (13f)21 (217 mg, 1.0 mmol, 1.2 equiv). After extraction 
and filtration through a silica plug, crude tert-butyl (2-(1-(3-bromophenyl)-N-
isobutylcycloprop-2-ene-1-carboxamido)ethyl)-carbamate (7ef) was used at the cyclization 
step as-is without additional purification. To this end, amide 7ef (60 mg, 0.137 mmol) was 
treated with powdered KOH (19.2 mg, 0.342 mmol). The reaction mixture was vigorously 
stirred at 35 °C for 8 h. The product was isolated by column chromatography eluting with a 
hexanes:E-tOAc mixture (2:1) as a colorless solid (Rf 0.48, mp 122−123 °C).
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Yield: 56.5 mg (0.129 mmol, 94%). 1H NMR (500 MHz, C6D6) δ7.39 (t, J = 1.9 Hz, 1H), 
7.18−7.15 (m, 1H), 7.06 (d, J = 7.9 Hz, 1H),6.76 (t, J = 7.9 Hz, 1H), 3.77 (br.t, J = 10.3 Hz, 
1H), 3.33−3.20 (m, 2H), 2.65 (dd, J = 13.4, 8.2 Hz, 1H), 2.51−2.43 (m, 1H), 2.37−2.29 (m, 
2H), 1.84 (t, J = 5.7 Hz, 1H), 1.67 (dh, J = 8.1, 6.7 Hz, 1H), 1.41 (s, 9H), 1.33 (t, J = 7.1 Hz, 
1H), 0.75 (dd, J = 6.7, 1.1 Hz, 6H). 13CNMR (126 MHz, C6D6) δ 169.1, 156.4, 142.1, 130.5 
(+), 130.1 (+), 128.7 (+), 124.8 (+), 123.3, 80.1, 53.8 (−), 44.5 (−), 44.4 (−), 37.2 (+), 36.4, 
28.4 (+, 3C), 28.0 (+), 26.6 (−), 20.3 (+), 20.1 (+). FTIR (NaCl, cm−1): 2964, 2928, 2871, 
1702, 1652, 1593, 1562, 1477, 1428, 1367, 1345, 1297, 1248, 1247, 1175, 1062, 856, 777, 
693, 664. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C21H29BrN2O3Na 459.1259; Found 
459.1263 (0.9 ppm).
tert-Butyl(1S*,8S*)-8-(3-Bromophenyl)-6-(4-fluorobenzyl)-7-oxo-2,6-
diazabicyclo[6.1.0]nonane-2-carboxylate (8ej).—This compound was synthesized 
according to the typical procedure starting from 1-(3-bromophenyl)cycloprop-2-ene-1-
carboxylic acid (12e)5 (200 mg, 0.84 mmol, 1.0 equiv) and tert-butyl (3-((4-fluorobenzyl)-
amino)propyl)carbamate (13j)22 (283 mg, 1 mmol, 1.2 equiv). After extraction and filtration 
through a silica plug, crude tert-butyl (3-(1-(3-bromophenyl)-N-(4-
fluorobenzyl)cycloprop-2-ene-1-carboxamido)propyl)carbamate (7ej) was used at the 
cyclization step as-is without additional purification. To this end, amide 7ej (60 mg, 0.119 
mmol) was treated with powdered KOH (16.7 mg, 0.298 mmol). The reaction mixture was 
vigorously stirred at 35 °C for 8 h. The product was isolated by column chromatography 
eluting with a hexanes:EtOAc mixture (3:1) as a colorless solid (Rf 0.27, mp 119−121 °C). 
Yield: 54.1 mg (0.107 mmol, 90%). 1H NMR (500 MHz, C6D6) δ 7.32 (s, 1H), 7.11 (d, J = 
7.1 Hz, 1H), 6.97 (dd, J = 8.1, 5.7Hz, 2H), 6.86 (d, J = 7.9 Hz, 1H), 6.79 (t, J = 8.6 Hz, 2H), 
6.68 (t, J = 7.9 Hz, 1H), 5.01 (d, J = 14.6 Hz, 1H), 3.86 (d, J = 14.3 Hz, 1H),3.59 (d, J = 14.6 
Hz, 1H), 3.28 (dd, J = 15.5, 11.2 Hz, 1H), 2.80−2.69 (m, 2H), 2.51 (dd, J = 15.5, 5.9 Hz, 
1H), 2.41 (ddd, J = 14.6, 11.5, 3.2 Hz, 1H), 1.68−1.56 (m, 1H), 1.43 (s, 9H), 1.19 (dd, J = 
8.5, 6.6 Hz, 1H), 0.92−0.82 (m, 1H). 13C NMR (126 MHz, C6D6) δ 169.2, 162.8 (d, J = 
245.3 Hz), 155.2, 143.3, 134.2 (d, J = 3.5 Hz), 130.5 (+), 130.3 (d, J = 8.1 Hz, + , 2C), 129.9 
(+), 128.7 (+), 124.2 (+), 123.5, 115.7 (d, J = 21.1 Hz, + , 2C), 80.2, 50.3 (−), 48.7 (−), 46.6 
(+), 46.2 (−), 37.0, 28.5 (+, 3C), 27.6 (−), 25.2 (−). FTIR (NaCl, cm−1): 2973, 2925, 1692, 
1639, 1593, 1562, 1509, 1477, 1414, 1383, 1367, 1256, 1221, 1154, 1107, 969, 858, 819, 
769, 689. 19F NMR (376 MHz, CDCl3) δ −114.8. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd 
for C25 H28 79BrFN2O3Na 525.1165; Found 525.1165 (0.0 ppm).
tert-Butyl(1S*,7S*)-6-Oxo-7-phenyl-5-(pyridin-2-ylmethyl)-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (8ag).—This compound was synthesized 
according to the typical procedure starting from 1-phenylcycloprop-2-ene-1-carboxylic acid 
(12a)15 (200 mg, 1.25 mmol, 1.0 equiv) and tert-butyl (2-((pyridin-2-ylmethyl)amino)-
ethyl)carbamate (13g)23 (377 mg, 1.5 mmol, 1.2 equiv). After extraction and filtration 
through a silica plug, crude tert-butyl (2-(1-phenyl-N-(pyridin-2-ylmethyl)cycloprop-2-
ene-1-carboxamido)-ethyl)carbamate (7af) was used at the cyclization step as-is without 
additional purification. To this end, amide 7af (60 mg, 0.152 mmol) was treated with 
powdered KOH (21.4 mg, 0.381 mmol). The reaction mixture was vigorously stirred at 
35 °C for 8 h. The product was isolated by column chromatography eluting with a 
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hexanes:E-tOAc mixture (1:2) as a colorless glass (Rf 0.31). Yield: 48.6 mg(0.123 mmol, 
81%). 1H NMR (500 MHz, C6D6) δ 8.37 (d, J = 4.8 Hz, 1H), 7.16 (s, 4H), 7.12−6.98 (m, 
3H), 6.66−6.59 (m, 1H), 4.65 (br.s, 2H), 3.65 (br.s, 1H), 3.51 (td, J = 14.8, 14.2, 3.8 Hz, 1H), 
2.88 (dd, J = 15.2, 4.9 Hz, 1H), 2.47−2.38 (m, 2H), 1.94 (t, J = 5.6 Hz, 1H), 1.53 (t, J = 6.8 
Hz, 1H), 1.39 (s, 9H). 13C NMR (126 MHz, C6D6) δ 169.8, 158.4, 159.4, 149.3 (+), 139.4, 
136.4 (+), 128.9 (+, 2C), 128.1, 126.9 (+), 125.8 (+, 2C), 122.8 (+), 122.3 (+), 79.8, 52.2 (−), 
44.6 (−), 44.6 (−), 37.7 (+), 36.2, 28.4 (+, 3C), 26.3 (−). FTIR (NaCl, cm−1): 2961, 2924, 
2854, 1700, 1654, 1591, 1474, 1435, 1394, 1366, 1345, 1251, 1146, 1066, 756, 698, 610. 
HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C23H27N3O3Na 416.195; Found 416.1958(1.9 
ppm).
tert-Butyl (1S*,8S*)-6-Benzyl-7-oxo-8-phenyl-2,6-diazabicyclo- [6.1.0]nonane-2-
carboxylate (8ah).—This compound was synthesized according to the typical procedure 
starting from 1-phenylcycloprop-2-ene-1-carboxylic acid (12a)15 (200 mg, 1.25 mmol, 1.0 
equiv) and tert-butyl (3-(benzylamino)propyl)carbamate (13h)17 (396 mg, 1.5 mmol, 1.2 
equiv). After extraction and filtration through a silica plug, crude tert-butyl (3-(N-benzyl-1-
phenylcycloprop-2-ene-1-carboxamido)propyl)carbamate (7ah) was used at the cyclization 
step as-is without additional purification. To this end, amide 7ah (60 mg, 0.148 mmol) was 
treated with powdered KOH (20.7 mg, 0.369 mmol). The reaction mixture was vigorously 
stirred at 35 °C for 8 h. The product was isolated by column chromatography eluting with a 
hexanes:EtOAc mixture (2:1) as a colorless solid (Rf 0.21, mp 110−112 °C). Yield: 50.5 mg 
(0.124 mmol, 84%). 1H NMR (500 MHz, C6D6) δ 7.18−7.16 (m, 4H), 7.13−6.98 (m, 6H), 
5.19 (d, J = 14.7Hz, 1H), 3.89 (br.d, J = 14.6 Hz, 1H), 3.84 (d, J = 14.7 Hz, 1H), 3.54 (dd, J 
= 15.3, 11.5 Hz, 1H), 3.03 (dd, J = 8.8, 6.0 Hz, 1H), 2.80−2.75 (m, 1H), 2.65 (dd, J = 15.4, 
5.6 Hz, 1H), 2.59 (ddd, J = 14.4, 11.3, 3.2 Hz, 1H), 1.76−1.65 (m, 1H), 1.46 (s, 9H), 1.33 
(dd, J = 8.8, 6.7 Hz, 1H), 0.98−0.89 (m, 1H). 13C NMR (126 MHz, C6D6) δ 170.0, 155.3, 
140.9, 138.7, 129.0 (+, 2C), 128.8 (+, 2C), 128.6 (+, 2C), 127.5 (+), 126.7 (+), 125.9 (+, 
2C), 80.0, 49.9 (−), 49.4 (−), 46.2 (+), 46.1 (−), 37.5, 28.5 (+, 3C), 27.6 (−), 24.8 (−). FTIR 
(NaCl, cm−1): 2925, 2854, 1692, 1640, 1631, 1585, 1470, 1453, 1416, 1383, 1366, 1288, 
1253, 1156, 1105, 1051, 939, 860, 788, 732, 699. HRMS (ESITOF) m/z: [M + Na]+ Calcd 
for C25H30N2O3Na 429.2154; Found 429.2164 (2.3 ppm).
tert-Butyl(1S*,8S*)-6-Benzyl-8-(2,4-dichlorophenyl)-7-oxo-2,6-
diazabicyclo[6.1.0]nonane-2-carboxylate (8fh).—This compound was synthesized 
according to the typical procedure starting from 1-(2,4-dichlorophenyl)cycloprop-2-ene-1-
carboxylic acid (12f)24 (200mg, 0.87 mmol, 1.0 equiv) and tert-butyl (3-
(benzylamino)propyl)-carbamate (13h)17 (278 mg, 1.05 mmol, 1.2 equiv). After extraction 
and filtration through a silica plug, crude tert-butyl (3-(N-benzyl-1-(2,4-
dichlorophenyl)cycloprop-2-ene-1-carboxamido)propyl)-carbamate (7fh) was used at the 
cyclization step as-is without additional purification. To this end, amide 7fh (60 mg, 0.126 
mmol) was treated with powdered KOH (17.7 mg, 0.316 mmol). The reaction mixture was 
vigorously stirred at 35 °C for 8 h. The product was isolated by column chromatography 
eluting with a hexanes:E-tOAc mixture (2:1) as a colorless solid (Rf 0.24, mp 118−120 °C). 
ield: 51.5 mg (0.108 mmol, 86%). 1H NMR (500 MHz, C6D6) δ7.48 (d, J = 8.5 Hz, 1H), 
7.12 (d, J = 2.3 Hz, 1H), 7.04−6.93 (m, 5H), 6.84 (dd, J = 8.4, 2.2 Hz, 1H), 5.01 (d, J = 14.9 
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Hz, 1H), 4.11 (t, J = 13.6 Hz, 1H), 3.88−3.73 (m, 2H), 3.20−3.06 (m, 2H), 2.71−2.63 (m, 
1H), 2.30 (t, J = 6.5 Hz, 1H), 1.47 (s, 9H), 1.39−1.31 (m, 1H),1.12 (dd, J = 8.9, 6.5 Hz, 1H), 
0.99−0.85 (m, 1H). 13C NMR (126MHz, C6D6) δ 169.7, 155.3, 138.4, 137.4, 135.2, 134.2 
(+), 134.0, 130.4 (+), 128.8 (+, 2C), 128.2 (+, 2C), 127.5 (+), 127.5 (+), 80.2,49.9 (−), 45.2 
(+), 44.7 (−), 44.0 (−), 35.7, 28.5 (+, 3C), 27.8 (−),21.3 (−). FTIR (NaCl, cm−1): 2972, 2925, 
2854, 1690, 1639, 1477, 1454, 1423, 1383, 1366, 1292, 1255, 1159, 1106, 1078, 1059, 968, 
860, 750, 733, 699, 602. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C25H28Cl2N2O3Na 
497.1375; Found 497.1382 (1.4 ppm).
tert-Butyl(1S*,8S*)-6-Benzyl-8-(3-bromophenyl)-7-oxo-2,6-
diazabicyclo[6.1.0]nonane-2-carboxylate (8eh).—This compound was synthesized 
according to the typical procedure starting from 1-(3-bromophenyl)cycloprop-2-ene-1-
carboxylic acid (12e)5 (200 mg, 0.84 mmol, 1.0 equiv) and tert-butyl (3-
(benzylamino)propyl)-carbamate (13h)17 (267 mg, 1 mmol, 1.2 equiv). After extraction and 
filtration through a silica plug, crude tert-butyl (3-(N-benzyl-1-(3-bromophenyl)cycloprop-2-
ene-1-carboxamido)propyl)carbamate (7eh) was used at the cyclization step as-is without 
additional purification. To this end, amide 7eh (60 mg, 0.124 mmol) was treated with 
powdered KOH (17.3 mg, 0.308 mmol). The reaction mixture was vigorously stirred at 
35 °C for 8 h. The product was isolated by column chromatography eluting with a 
hexanes:EtOAc mixture (2:1) as a colorless solid (Rf 0.24, mp 121−123 °C). Yield: 49.8 mg 
(0.103 mmol, 83%). 1H NMR (500 MHz, C6D6) δ 7.39 (s, 1H), 7.16−7.11 (m, 5H), 7.06 (t, J 
= 6.7 Hz, 1H), 6.94 (d, J = 7.9 Hz, 1H), 6.71 (t, J = 7.9 Hz, 1H), 5.19 (d, J = 14.7 Hz, 1H), 
3.87 (br.d, J = 14.3 Hz, 1H),3.73 (d, J = 14.7 Hz, 1H), 3.32 (dd, J = 15.5, 11.1 Hz, 1H), 2.80 
(dd, J = 8.3, 6.3 Hz, 1H), 2.75 (t, J = 6.3 Hz, 1H), 2.61 (dd, J = 15.2, 5.7 Hz, 1H), 2.43 (ddd, 
J = 14.4, 11.6, 3.0 Hz, 1H), 1.73−1.61 (m, 1H), 1.45 (s, 9H), 1.21 (dd, J = 8.6, 6.7 Hz, 1H), 
0.92−0.84 (m, 1H). 13C NMR (126 MHz, C6D6) δ 169.2, 155.2, 143.4, 138.4, 130.5 (+), 
129.9 (+), 128.9 (+, 2C), 128.7 (+), 128.6 (+, 2C), 127.6 (+), 124.3 (+), 123.4,80.2, 50.2 (−), 
49.4 (−), 46.6 (+), 46.1 (−), 37.1, 28.5 (+, 3C), 27.5 (−), 25.3 (−). FTIR (NaCl, cm−1): 2972, 
2925, 1691, 1639, 1593, 1561, 1476, 1454, 1418, 1383, 1366, 1282, 1256, 1158, 1106, 
1078, 968, 860, 768, 752, 700. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C H 7925 29 
BrN2O3Na 507.1259; Found 507.1255 (0.8 ppm).
tert-Butyl (1S*,7S*)-5-Methyl-6-oxo-7-phenyl-2,5-diazabicyclo- [5.1.0]octane-2-
carboxylate (8ad).—This compound was synthesized according to the typical procedure 
starting from 1-phenylcycloprop-2-ene-1-carboxylic acid (12a)15 (200 mg, 1.25 mmol, 1.0 
equiv) and tert-butyl (2-(methylamino)ethyl)carbamate (13d)25(261 mg, 1.5 mmol, 1.2 
equiv). After extraction and filtration through a silica plug, crude tert-butyl (2-(N-methyl-1-
phenylcycloprop-2-ene-1-carboxamido)ethyl)carbamate (7ad) was used at the cyclization 
step as-is without additional purification. To this end, amide 7ad (60 mg, 0.19 mmol) was 
treated with powdered KOH (26.6 mg, 0.474 mmol). The reaction mixture was vigorously 
stirred at 35 °C for 8 h. The product was isolated by column chromatography eluting with a 
hexanes:EtOAc mixture (2:1) as a colorless solid (Rf 0.42, mp 188−189 °C). Yield: 54.6 mg 
(0.173 mmol, 91%). 1H NMR (500 MHz, C6D6) δ 7.15−7.06 (m, 4H), 7.03 (dd, J = 8.1, 6.0 
Hz, 1H), 3.79 (br.t, J = 11.4 Hz, 1H), 3.43 (ddd, J = 15.5, 13.7, 3.7 Hz, 1H), 2.58 (s, 3H),
2.52−2.43 (m, 2H), 2.17 (dd, J = 15.4, 4.7 Hz, 1H), 1.87 (t, J = 5.3 Hz, 1H), 1.46 (t, J = 6.7 
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Hz, 1H), 1.41 (s, 9H). 13C NMR (126 MHz, C6D6) δ 169.5, 156.7, 139.5, 128.9 (+, 2C), 
127.0 (+), 125.9 (+, 2C),80.0, 45.5 (−), 43.6 (−), 37.3 (+), 36.4, 33.3 (+), 28.5 (+, 3C), 26.3 
(−). FTIR (NaCl, cm−1): 2974, 2928, 1698, 1655, 1479, 1432, 1396, 1357, 1345, 1251, 
1175, 1146, 1067, 856, 775, 758, 698, 615. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C18H24N2O3Na 339.1685; Found 339.1696 (3.2 ppm).
tert-Butyl(1S*,7S*)-7-(3-Bromophenyl)-5-methyl-6-oxo-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (8ed).—This compound was synthesized 
according to the typical procedure starting from 1-(3-bromophenyl)cycloprop-2-ene-1-
carboxylic acid (12e)5 (200 mg, 0.84 mmol, 1.0 equiv) and tert-butyl (2-
(methylamino)ethyl)-carbamate (13d)24 (175 mg, 1 mmol, 1.2 equiv). After extraction and 
filtration through a silica plug, crude tert-butyl (2-(1-(3-bromophenyl)-N-
methylcycloprop-2-ene-1-carboxamido)ethyl)-carbamate (7ed) was used at the cyclization 
step as-is without additional purification. To this end, amide 7ed (60 mg, 0.152 mmol) was 
treated with powdered KOH (21.3 mg, 0.38 mmol). The reaction mixture was vigorously 
stirred at 35 °C for 8 h. The product was isolated by column chromatography eluting with a 
hexanes:EtOAc mixture (1:1) as a colorless solid (Rf 0.39, mp 115−117 °C). Yield:54.1 mg 
(0.137 mmol, 90%). 1H NMR (500 MHz, C6D6) δ 7.36−7.31 (m, 1H), 7.19−7.15 (m, 1H), 
7.06 (d, J = 7.9 Hz, 1H), 6.75 (t, J = 7.9 Hz, 1H), 3.72 (br.t, J = 10.6 Hz, 1H), 3.34−3.23 (m, 
1H), 2.52 (s, 3H), 2.42 (dd, J = 13.1, 3.8 Hz, 1H), 2.33−2.28 (m, 1H), 2.13 (dd, J = 15.3, 4.4 
Hz, 1H), 1.80 (t, J = 5.6 Hz, 1H), 1.40 (s, 9H), 1.31 (t, J = 7.0 Hz, 1H). 13C NMR (126 
MHz, C6D6) δ 168.9, 156.6, 142.0, 130.5 (+), 130.2 (+), 128.6 (+), 125.1 (+), 123.3, 80.1, 
45.4 (−), 43.5 (−), 37.0 (+), 36.1, 33.3 (+), 28.4 (+, 3C), 26.4 (−). FTIR (NaCl, cm−1): 2974, 
2928, 1699, 1657, 1593, 1563, 1478, 1394, 1356, 1342, 1250, 1174, 1147, 1082, 1054, 856, 
778, 695, 664. HRMS (ESITOF) m/z: [M + Na]+ Calcd for C H 7918 23 BrN2O3Na 
417.0790; Found 417.0786 (1.0 ppm).
tert-Butyl(1S*,7S*)-7-(2,4-Dichlorophenyl)-5-methyl-6-oxo-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (8fd).—This compound was synthesized 
according to the typical procedure starting from 1-(2,4-dichlorophenyl)cycloprop-2-ene-1-
carboxylic acid23 (12f) (200 mg, 0.87 mmol, 1.0 equiv) and tert-butyl (2-
(methylamino)ethyl)-carbamate (13d)24 (183 mg, 1.05 mmol, 1.2 equiv). After extraction 
and filtration through a silica plug, crude tert-butyl (2-(1-(2,4-dichlorophenyl)-N-
methylcycloprop-2-ene-1-carboxamido)ethyl)-carbamate (7ed) was used at the cyclization 
step as-is without additional purification. To this end, amide 7ed (60 mg, 0.156 mmol) was 
treated with powdered KOH (21.8 mg, 0.389 mmol). The reaction mixture was vigorously 
stirred at 35 °C for 8 h. The product was isolated by column chromatography eluting with a 
hexanes:E-tOAc mixture (1:1) as a colorless solid (Rf 0.42, mp 180−181 °C). Yield: 52.2 mg 
(0.136 mmol, 87%). 1H NMR (500 MHz, C6D6) δ7.48 (d, J = 8.5 Hz, 1H), 7.12 (d, J = 2.0 
Hz, 1H), 6.85 (dd, J = 8.5,2.0 Hz, 1H), 4.16−4.06 (m, 1H), 3.82 (br.t, J = 11.7 Hz, 1H), 
2.99−2.95 (m, 1H), 2.78−2.72 (m, 1H), 2.48 (s, 3H), 2.27 (dd, J = 15.4,4.4 Hz, 1H), 1.73 
(br.s, 1H), 1.40 (s, 9H), 1.27 (br.s, 1H). 13C NMR (126 MHz, C6D6) δ 168.7, 156.6, 135.3, 
134.8, 134.4 (+), 134.0, 130.7 (+), 127.4 (+), 80.1, 45.3 (−), 43.8 (−), 36.0 (+), 35.6, 34.2 
(+), 28.4 (+, 3C), 26.3 (−). FTIR (NaCl, cm−1): 2974, 2929, 1700, 1656, 1474, 1428, 1380, 
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1366, 1277, 1253, 1174, 1145, 1107, 1079, 858, 829, 781. HRMS (ESI-TOF) m/z: [M + Na]
+ Calcd for C18H22Cl2N2O3Na 407.0905; Found 407.0921 (3.9 ppm).
tert-Butyl(1S*,7S*)-5-Benzyl-7-(2,4-dichlorophenyl)-6-oxo-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (8fa).—This compound was synthesized 
according to the typical procedure starting from 1-(2,4-dichlorophenyl)cycloprop-2-ene-1-
carboxylic acid23 (12f) (200mg, 0.87 mmol, 1.0 equiv) and tert-butyl (2-
(benzylamino)ethyl)-carbamate (13a)16 (262 mg, 1.05 mmol, 1.2 equiv). After extraction 
and filtration through a silica plug, crude tert-butyl (2-(N-benzyl-1-(2,4-
dichlorophenyl)cycloprop-2-ene-1-carboxamido)ethyl)carbamate (7fa) was used at the 
cyclization step as-is without additional purification. To this end, amide 7fa (60 mg, 0.13 
mmol) was treated with powdered KOH (18.2 mg, 0.324 mmol). The reaction mixture was 
vigorously stirred at 35 °C for 8 h. The product was isolated by column chromatography 
eluting with a hexanes:EtOAc mixture (3:1) as a colorless solid (Rf 0.33, mp 92−93 °C). 
Yield: 50.9 mg (0.11 mmol, 85%). 1H NMR (500 MHz, C6D6) δ 7.53 (d, J = 8.4 Hz, 1H),
7.12 (d, J = 2.3 Hz, 1H), 7.06−6.97 (m, 5H), 6.86 (dd, J = 8.5, 2.3 Hz, 1H), 4.34 (br.s, 1H), 
4.28 (br.s, 1H), 4.09 (td, J = 13.2, 3.7 Hz, 1H), 3.61 (br.s, 1H), 2.99 (dd, J = 7.2, 4.4 Hz, 1H), 
2.72−2.64 (m, 1H), 2.61−2.53 (m, 1H), 1.84 (t, J = 5.4 Hz, 1H), 1.41 (s, 9H),1.38−1.34 (m, 
1H). 13C NMR (126 MHz, C6D6) δ 169.2, 156.4, 138.0, 135.3, 134.8, 134.5 (+), 134.1, 
130.8 (+), 128.9 (+, 2C), 128.2 (+, 2C), 127.7 (+), 127.5 (+), 80.0, 50.4 (−), 44.5 (−), 43.2 
(−),36.3 (+), 35.7, 28.4 (+, 3C), 26.4 (−). FTIR (NaCl, cm−1): 2973, 2927, 1701, 1653, 1585, 
1473, 1419, 1392, 1366, 1346, 1253, 1168, 1145, 1107, 1078, 1046, 992, 858, 820, 784, 
734, 700. HRMS (ESITOF) m/z: [M + Na]+ Calcd for C24H26Cl2N2O3Na 483.1218; Found 
483.1214 (0.8ppm).
tert-Butyl(1S*,7S*)-5-Benzyl-7-(4-methoxyphenyl)-6-oxo-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (8ba).—This compound was synthesized 
according to the typical procedure starting from 1-(4-methoxyphenyl)cycloprop-2-ene-1-
carboxylic acid (12b) (200 mg, 1.05 mmol, 1.0 equiv) and tert-butyl (2-(benzylamino)ethyl)-
carbamate (13a)16 (316 mg, 1.26 mmol, 1.2 equiv). After extraction and filtration through a 
silica plug, crude tert-butyl (2-(N-benzyl-1-(4-methoxyphenyl)cycloprop-2-ene-1-
carboxamido)ethyl)carbamate (7ba) was used at the cyclization step as-is without additional 
purification. To this end, amide 7ba (60 mg, 0.142 mmol) was treated with powdered KOH 
(19.9 mg, 0.355 mmol). The reaction mixture was vigorously stirred at 35 °C for 8 h. The 
product was isolated by column chromatography eluting with a hexanes:EtOAc mixture 
(3:1) as a colorless solid (Rf 0.26, mp 103−105 °C). Yield: 51.5 mg (0.122 mmol, 86%). 1H 
NMR (500 MHz, C6D6) δ 7.15−7.07 (m, 6H),7.07−7.02 (m, 1H), 6.77−6.73 (m, 2H), 4.60 
(br.s, 1H), 4.25 (br.s, 1H), 3.61 (br.s, 1H), 3.51 (td, J = 14.4, 2.2 Hz, 1H), 3.33 (s, 3H),
2.58−2.41 (m, 3H), 1.96 (t, J = 5.4 Hz, 1H), 1.50 (t, J = 6.4 Hz, 1H),1.43 (s, 9H). 13C NMR 
(126 MHz, C6D6) δ 170.2, 159.3, 156.6, 138.5, 131.2, 128.9 (+, 2C), 128.3 (+, 2C), 127.6 
(+), 127.2 (+, 2C), 114.7 (+, 2C), 79.8, 55.0 (+), 49.5 (−), 44.6 (−), 43.4 (−), 36.8 (+),35.9, 
28.5 (+, 3C), 26.1 (−). FTIR (NaCl, cm−1): 2974, 2928, 1700, 1651, 1515, 1496, 1428, 1393, 
1366, 1346, 1250, 1179, 1146, 1065, 1030, 829, 777, 731, 701. HRMS (ESI-TOF) m/z: [M 
+ Na]+ Calcd for C25H30N2O4Na 445.2103; Found 445.2098 (1.1 ppm).
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diazabicyclo[5.1.0]octane-2-carboxylate (8da).—This compound was synthesized 
according to the typical procedure starting from 1-(3-chlorophenyl)cycloprop-2-ene-1-
carboxylic acid (12d) (200 mg, 1.03 mmol, 1.0 equiv) and tert-butyl (2-(benzylamino)ethyl)-
carbamate (13a)16 (309 mg, 1.23 mmol, 1.2 equiv). After extraction and filtration through a 
silica plug, crude tert-butyl (2-(N-benzyl-1-(3-chlorophenyl)cycloprop-2-ene-1-
carboxamido)ethyl)carbamate (7da) was used at the cyclization step as-is without additional 
purification. To this end, amide 7da (60 mg, 0.141 mmol) was treated with powdered KOH 
(19.7 mg, 0.351 mmol). The reaction mixture was vigorously stirred at 35 °C for 8 h. The 
product was isolated by column chromatography eluting with a hexanes:EtOAc mixture 
(1:1) as a colorless solid (Rf 0.4, mp 100−102 °C). Yield: 52.9 mg (0.124 mmol, 88%). 1H 
NMR (500 MHz, C6D6) δ 7.21 (s, 1H), 7.1−7.1 (m, 4H), 7.05 (t, J = 6.4 Hz, 1H), 7.02−6.98 
(m, 2H), 6.81 (t, J = 7.9 Hz, 1H), 4.50 (br.s, 1H), 4.19 (br.s, 1H), 3.51 (br.s, 1H), 3.22 (td, J = 
13.3, 4.1 Hz, 1H), 2.44 (dd, J = 15.5, 5.0 Hz, 1H), 2.35 (dd, J = 12.9,4.0 Hz, 1H), 2.31 (dd, J 
= 7.2, 4.7 Hz, 1H), 1.92 (t, J = 5.7 Hz, 1H),1.41 (sk, 9H), 1.39−1.29 (m, 1H). 13C NMR (126 
MHz, C6D6) δ 169.2, 156.3, 141.7, 138.2, 135.2, 130.2 (+), 128.9 (+, 2C), 128.4 (+, 2C), 
127.7 (+), 127.2 (+), 125.8 (+), 124.3 (+), 80.0, 49.6 (−), 44.3 (−), 43.4 (−), 37.4 (+), 36.1, 
28.4 (+, 3C), 26.6 (−). FTIR (NaCl, cm−1): 2974, 2926, 2855, 1699, 1651, 1593, 1510, 1478, 
1392, 1366, 1344, 1248, 1223, 1148, 1065, 993, 852, 815, 777, 736. HRMS (ESITOF) m/z: 
[M + Na]+ Calcd for C24H27ClN2O3Na 449.1608; Found 449.1618, (1.0 ppm).
tert-Butyl(1S*,7S*,8R*)-5-Benzyl-6-oxo-7,8-diphenyl-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (8ga).—This compound was synthesized 
according to the typical procedure starting from 1,2-diphenylcycloprop-2-ene-1-carboxylic 
acid (12g)26 (150 mg, 0.63 mmol, 1.0 equiv) and tert-butyl (2-(benzylamino)ethyl)carbamate 
(13a)16 (191 mg, 0.76 mmol, 1.2 equiv). After extraction and filtration through a silica plug, 
crude tert-butyl (2-(N-benzyl-1,2-diphenylcycloprop-2-ene-1-carboxamido)ethyl)carbamate 
(7ga) was used at the cyclization step as-is without additional purification. To this end, 
amide 7ga (50 mg, 0.107 mmol) was treated with powdered KOH (15 mg, 0.267 mmol). The 
reaction mixture was vigorously stirred at 50 °C for 16 h. The product was isolated by 
column chromatography eluting with a hexanes:EtOAc mixture (2:1) as a colorless solid (Rf 
0.43, mp 183−184 °C). Yield: 45.6 mg (0.097 mmol, 91%). 1H NMR (500 MHz, C6D6) δ 
7.31 (d, J = 7.6 Hz, 2H),7.20 (br. s, 2H), 7.10−6.98 (m, 5H), 6.96 (t, J = 7.6 Hz, 4H), 6.87 (t, 
J = 7.3 Hz, 2H), 4.51 (br. s, 1H), 4.25 (br. s, 1H), 3.80−3.56 (m, 2H), 3.37 (d, J = 4.7 Hz, 
1H), 3.22 (d, J = 4.7 Hz, 1H), 2.62 (d, J = 9.2 Hz, 1H), 2.49 (d, J = 10.6 Hz, 1H), 1.34 (s, 
9H). 13C NMR (126 MHz, C6D6) δ 170.3, 156.9, 138.2, 136.1, 134.7, 129.4 (+, 2C), 128.8 
(+, 2C), 128.8 (+, 2C), 128.6 (+, 2C), 128.4 (+, 2C), 128.0 (+, 2C), 127.6 (+), 127.4 (+), 
126.6 (+), 80.2, 49.8 (−), 44.6 (−), 44.6, 43.1 (−), 40.9 (+), 39.1 (+), 28.5 (+, 3C). FTIR 
(NaCl, cm−1): 2976, 2926, 2868, 1701, 1647, 1496, 1469, 1423, 1363, 1252, 1170, 1142, 
777, 735, 698. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C30H32N2O3Na 491.2311; 
Found 491.2318 (1.4 ppm).
tert-Butyl(1S*,8S*,9R*)-6-Benzyl-7-oxo-8,9-diphenyl-2,6-
diazabicyclo[6.1.0]nonane-2-carboxylate (8gh).—This compound was synthesized 
according to the typical procedure starting from 1,2-diphenylcycloprop-2-ene-1-carboxylic 
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acid (12g)25 (150 mg, 0.63 mmol, 1.0 equiv) and tert-butyl (3-
(benzylamino)propyl)carbamate (13h)17 (202 mg, 0.76 mmol, 1.2 equiv). After extraction 
and filtration through a silica plug, crude tert-butyl (3-(N-benzyl-1,2-diphenylcycloprop-2-
ene-1-carboxamido)propyl)carbamate (7gh) was used at the cyclization step as-is without 
additional purification. To this end, amide 7gh (50 mg, 0.104 mmol) was treated with 
powdered KOH (14.5 mg, 0.258 mmol). The reaction mixture was vigorously stirred at 
50 °C for 16 h. The product was isolated by column chromatography eluting with a 
hexanes:EtOAc mixture (2:1) as a colorless solid (Rf 0.4, mp 98−99 °C). Yield: 43.9 mg 
(0.091 mmol, 88%). 1H NMR (500 MHz, CDCl3) δ 7.42−7.17 (m, 15H),5.39 (d, J = 15.0 
Hz, 1H), 4.20 (d, J = 15.0 Hz, 1H), 4.22 (br. s, 1H),4.09 (dd, J = 15.3, 11.5 Hz, 1H), 4.05 (br. 
s, 1H), 3.78 (d, J = 6.5 Hz, 1H), 3.54 (ddd, J = 14.2, 9.7, 3.2 Hz, 1H), 3.19 (ddd, J = 15.4, 
5.3, 2.3 Hz, 1H), 2.08−1.97 (m, 1H), 1.89−1.78 (m, 1H), 1.60 (s, 9H). 13C NMR (126 MHz, 
CDCl3) δ 171.1, 156.2, 137.5, 135.8, 135.2, 128.8 (+, 2C), 128.6 (+, 2C), 128.4 (+, 4C), 
127.9 (+, 4C), 127.4 (+), 127.2 (+), 126.3 (+), 80.9, 49.4 (−, 2C), 47.7 (+), 45.7 (−), 
45.4,36.8 (+), 28.6 (+, 3C), 28.3 (−). FTIR (NaCl, cm−1): 2976, 2928, 1694, 1634, 1477, 
1417, 1365, 1294, 1258, 1155, 1078, 735, 698. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C31H34N2O3Na 505.2467; Found 505.2472 (1.0 ppm).
tert-Butyl(1S*,7S*,8R*)-5-Benzyl-7-(2,4-dichlorophenyl)-6-oxo-8-phenyl-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (8ha).—This compound was synthesized 
according to the typical procedure starting from 1-(2,4-dichlorophenyl)-2-
phenylcycloprop-2-ene-1-carboxylic acid (12h) (150 mg, 0.49 mmol, 1.0 equiv) and tert-
butyl (2-(benzylamino)ethyl)carbamate (13a)16 (148 mg, 0.59 mmol, 1.2 equiv). After 
extraction and filtration through a silica plug, crude tert-butyl (2-(N-benzyl-1-(2,4-
dichlorophenyl)-2-phenylcycloprop-2-ene-1-carboxamido)ethyl)carbamate (7ha) was used at 
the cyclization step as-is without additional purification. To this end, amide 7ha (50 mg, 
0.093 mmol) was treated with powdered KOH (13 mg, 0.232 mmol). The reaction mixture 
was vigorously stirred at 50 °C for 16 h. The product was isolated by column 
chromatography eluting with a hexanes:EtOAc mixture (4:1) as a colorless glass (Rf 0.33). 
Yield: 38.5 mg (0.072 mmol, 77%). 1H NMR (500 MHz, C6D6) δ 7.71 (d, J = 8.5 Hz, 1H), 
7.03 (d, J = 9.7 Hz, 6H), 6.97−6.89 (m, 4H), 6.89−6.79 (m, 1H), 6.71−6.55 (m, 1H), 
4.48−4.27 (m, 3H), 3.93 (d, J = 4.8 Hz, 1H), 3.78 (br. s, 1H), 3.20 (br. s, 1H), 2.85−2.80 (m, 
1H), 2.64 (dd, J = 15.6, 5.3 Hz, 1H), 1.28 (s, 9H). 13C NMR (126 MHz, C6D6) δ 169.8, 
156.6, 137.8, 136.6 (+), 136.3, 134.6, 134.2, 130.6, 130.4 (+), 128.9 (+, 2C), 128.6 (+, 2C), 
128.2 (+, 2C), 128.2 (+, 2C), 127.7 (+), 127.6 (+), 126.8 (+), 80.2, 50.5 (−), 44.3 (−), 44.3, 
43.0 (−),42.2 (+), 41.1 (+), 28.4 (+, 3C). FTIR (NaCl, cm−1): 2974, 2926, 2864, 1701, 1649, 
1473, 1386, 1365, 1250, 1142, 812, 736, 696. HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C30H30Cl2N2O3Na 559.1531; Found 559.1539 (1.4 ppm).
tert-Butyl(1S*,7S*,8R*)-7-(2,4-Dichlorophenyl)-5-(4-methoxybenzyl)-6-oxo-8-
phenyl-2,5-diazabicyclo[5.1.0]octane-2-carboxy-late (8hb).—This compound was 
synthesized according to the typical procedure starting from 1-(2,4-dichlorophenyl)-2-
phenylcycloprop-2-ene-1-carboxylic acid (12h) (150 mg, 0.49 mmol, 1.0 equiv) and tert-
butyl (2-((4-methoxybenzyl)amino)ethyl)carbamate (13b)17 (165mg, 0.59 mmol, 1.2 equiv). 
After extraction and filtration through a silica plug, crude tert-butyl (2-(1-(2,4-
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carboxamido)ethyl)carbamate (7hb) was used at the cyclization step as-is without additional 
purification. To this end, amide 7hb (50 mg, 0.088 mmol) was treated with powdered KOH 
(12.4 mg, 0.221 mmol). The reaction mixture was vigorously stirred at 50 °C for 16 h. The 
product was isolated by column chromatography eluting with a hexanes:EtOAc mixture 
(5:1) as a colorless glass (Rf 0.33). Yield: 40.5 mg (0.071 mmol, 81%). 1H NMR (500 MHz, 
C6D6) δ 7.73 (d, J = 8.6 Hz, 1H), 7.02 (d, J = 2.2 Hz, 1H), 7.00 (d, J = 8.3 Hz, 2H), 
6.96−6.90 (m, 4H), 6.85 (ddd, J = 8.5, 5.7, 2.3 Hz, 1H), 6.68 (d, J = 8.6 Hz, 2H), 6.64 (dd, J 
= 8.6, 2.3 Hz, 1H), 4.36 (ddd, J = 15.4, 13.2, 4.4 Hz, 1H), 4.36 (br. s, 2H), 3.93 (d, J = 4.7 
Hz, 1H), 3.79 (s, 1H), 3.27 (s, 3H), 3.21 (br. s, 1H), 2.85 (dd, J = 13.1, 4.2 Hz, 1H), 2.70 (dd, 
J = 15.6, 5.2 Hz, 1H), 1.28 (s, 9H). 13C NMR (126 MHz, C6D6) δ 169.7, 159.8, 156.6, 136.6 
(+), 136.3, 134.6, 134.2, 130.7, 130.4 (+), 129.8, 129.6 (+, 2C), 128.4 (+, 2C), 128.2 (+, 2C), 
127.6 (+), 126.8 (+), 114.6 (+, 2C), 80.2, 54.8 (+), 50.0 (−), 44.4 (−), 44.4, 42.8 (−), 42.2 
(+), 41.1 (+), 28.4 (+, 3C). FTIR (NaCl, cm−1): 2974, 2928, 1701, 1647, 1512, 1474, 1364, 
1248, 2242, 1035, 810, 769, 736, 696. HRMS (ESI-TOF) m/z: [M +Na]+ Calcd for 
C31H32Cl2N2O4Na 589.1637; Found 589.1639 (0.3 ppm).
tert-Butyl(1S*,8S*,9R*)-8-(2,4-Dichlorophenyl)-6-(4-methoxybenzyl)-7-oxo-9-
phenyl-2,6-diazabicyclo[6.1.0]nonane-2-carboxy-late (8hi).—This compound was 
synthesized according to the typical procedure starting from 1-(2,4-dichlorophenyl)-2-
phenylcycloprop-2-ene-1-carboxylic acid (12h) (150 mg, 0.49 mmol, 1.0 equiv) and tert-
butyl (3-((4-methoxybenzyl)amino)propyl)carbamate (13i)17 (173mg, 0.59 mmol, 1.2 
equiv). After extraction and filtration through a silica plug, crude tert-butyl (3-(1-(2,4-
dichlorophenyl)-N-(4-methoxybenzyl)-2-phenylcycloprop-2-ene-1-
carboxamido)propyl)carbamate (7hi) was used at the cyclization step as-is without 
additional purification. To this end, amide 7hi (50 mg, 0.086 mmol) was treated with 
powdered KOH (12.1 mg, 0.216 mmol). The reaction mixture was vigorously stirred at 
50 °C for 16 h. The product was isolated by column chromatography eluting with a 
hexanes:EtOAc mixture (5:1) as a colorless glass (Rf 0.25). Yield: 37.9 mg (0.065 mmol, 
76%). 1H NMR (500 MHz, C6D6) δ 7.46 (d, J = 8.4 Hz, 1H), 7.11 (d, J = 7.7 Hz, 2H), 7.04 
(d, J = 1.7 Hz, 1H), 7.00−6.93 (m, 4H), 6.88 (t, J = 7.3 Hz, 1H), 6.64 (d, J = 8.5 Hz, 2H), 
6.65−6.63 (m, 1H), 5.02 (d, J = 14.6 Hz, 1H), 4.61 (br. s, 1H), 4.21 (t, J = 13.3 Hz, 2H), 3.91 
(br. s, 1H), 3.83 (d, J = 14.6 Hz, 1H), 3.47 (br. s, 1H), 3.35 (br. s, 1H), 3.24 (s, 3H), 2.77 (dt, 
J = 15.2, 3.1 Hz, 1H), 1.70−1.27 (m, 2H), 1.44 (s, 9H). 13C NMR (126 MHz, C6D6) δ 170.1, 
159.7, 155.6, 136.3, 135.4 (+), 134.0, 132.6, 130.6 (+), 130.2, 129.6 (+, 2C), 128.4 (+, 2C), 
128.4 (+, 2C), 127.2 (+), 126.9 (+), 114.4 (+, 2C), 80.3, 54.8 (+),49.5 (−), 49.1 (+), 45.0, 
44.8 (−, 2C), 37.2 (+), 28.5 (−), 28.5 (+, 3C). FTIR (NaCl, cm−1): 2974, 2928, 1695, 1636, 
1512, 1471, 1413, 1365, 1246, 1153, 1105, 1033, 158, 808, 767, 696. HRMS (ESI-TOF) 
m/z: [M + Na]+ Calcd for C32H34Cl2N2O4Na 603.1793; Found 603.1793 (0.0 ppm).
tert-Butyl(1S,4S,7S)-5-Benzyl-7-(4-fluorophenyl)-4-isopropyl-6-oxo-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (8ck).—This compound was synthesized 
according to the typical procedure from 1-(4-fluorophenyl)cycloprop-2-ene-1-carboxylic 
acid (12c) (100 mg, 0.56 mmol, 1.0 equiv) and tert-butyl (S)-(2-(benzylamino)-3-
methylbutyl)carbamate (13k) (197 mg, 0.67 mmol, 1.2 equiv). After extraction and filtration 
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through a silica plug, crude tert-butyl (S)-(2-(N-benzyl-1-(4-fluorophenyl)cycloprop-2-
ene-1-carboxamido)-3-methylbutyl)carbamate (7ck) was used at the cyclization step as-is 
without additional purification. To this end, amide 7ck (50 mg, 0.11 mmol) was treated with 
powdered KOH (15.5 mg, 0.276 mmol). The reaction mixture was vigorously stirred at 
50 °C for 16 h. The product was isolated by column chromatography eluting with a 
hexanes:EtOAc mixture (5:1) as a colorless solid (Rf 0.33, mp 155−157 °C), [α] 20D +97.8° 
(c 0.90, CHCl3). Yield: 44.6 mg (0.099 mmol, 89%). 1H NMR (400 MHz, CDCl3) δ 
7.32−7.21 (m, 5H), 7.14−7.06 (m, 2H), 7.05−6.97 (m, 2H), 5.44 (br. d, J = 15.1 Hz, 1H), 
3.99 (br. d, J = 15.2 Hz, 1H), 3.54 (ddd, J = 12.6, 10.3, 3.9 Hz, 1H), 3.01 (br. s, 1H), 2.86 
(dd, J = 12.6, 3.9 Hz, 1H), 2.60 (dd, J = 7.1, 4.6 Hz, 1H),2.20−2.05 (m, 1H), 1.91 (dd, J = 
7.0, 4.6 Hz, 1H), 1.79 (t, J = 7.1 Hz, 1H), 1.69 (s, 1H), 1.42 (s, 9H), 0.88 (dd, J = 10.1, 6.4 
Hz, 6H). 13C NMR (151 MHz, CDCl3) δ 172.1, 161.8 (d, J = 245.8 Hz), 156.4, 138.4, 134.0 
(d, J = 3.1 Hz), 128.7 (+, 2C), 127.9 (+), 127.4 (+, 2C), 126.2 (d, J = 8.1 Hz, + , 2C), 115.7 
(d, J = 21.5 Hz, + , 2C), 80.5, 61.1 (+), 46.9 (−), 44.3 (−), 39.0 (+), 35.2, 28.3 (+, 3C), 27.4 
(−), 21.9 (+, 2C), 19.9 (+). 19F NMR (376 MHz, CDCl3) δ − 115.7. FTIR (NaCl, cm−1): 
2973, 2929, 1701, 1649, 1513, 1368, 1147, 832, 730. HRMS (ESI-TOF) m/z: [M + Na]+ 
Calcd for C27H33FN2O3Na 475.2373; Found 475.2375 (0.4 ppm).
3-(N-Benzyl-1-phenylcycloprop-2-ene-1-carboxamido)propan-1-aminium 
Chloride (9).—Gaseous hydrogen chloride was bubbled through a solution of crude (3-(N-
benzyl-1-phenylcycloprop-2-ene-1-carboxamido)propyl)carbamate (7ah) (589 mg, 1.45 
mmol) in dichloromethane (25 mL) while stirring at rt. The reaction was allowed to proceed 
until TLC analysis indicated consumption of the starting carbamate (45 min). Volatiles were 
removed under reduced pressure. The resultant solid was triturated with diethyl ether and 
collected via vacuum filtration to afford the title compound as a white crystalline material 
(390 mg, 1.14 mmol, 79%); mp 89.1 °C (dec.); NMR spectra indicate the presence of two 
rotamers (ratio of 1.4:1): 1H NMR (500 MHz, DMSO-d6) δ [7.93 (s) and 7.89 (s) and 
7.62(s), ∑5H], [7.38−7.17 (m) and 7.12−7.05 (m) and 7.01−6.98 (m), ∑10H], [4.54 (s) and 
4.52 (s), ∑2H], [3.26 (t, J = 7.9 Hz) and 3.21 (t, J = 7.2 Hz), ∑2H], [2.71 (q, J = 6.6 Hz) and 
2.54 (q, J = 6.4 Hz), ∑2H], [1.78 (p, J = 7.4 Hz) and 1.72−1.64 (m), ∑2H]; FT IR (NaCl, cm
−1): 3122, 3084, 2817, 2788, 2712, 1590, 1531, 1441, 1430, 1367, 1242, 738, 709, 696, 662, 
537; HRMS (ESI-TOF) m/z: [M]+ Calcd for C20H23N2O 307.1810; Found 307.1827 (5.5 
ppm).
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ORTEP drawings of 8ck (CCDC #1854746) showing atom numbering schemes and 50% 
probability ellipsoids. Boc-group at N1 is removed for clarity. Also, see Supporting 
Information for X-ray data of compounds 8da (CCDC #1854743), 8ga (CCDC #1854744), 
and 8ej (CCDC #1854745).
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Nucleophilic Additions to Cyclopropenes
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Decomposition of the Product of Intramolecular Nucleophilic Addition of Primary Amine to 
Cyclopropene
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7-exo-trig Cyclization of Tethered Carbamates
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8-exo-trig Cyclization of Tethered Carbamates
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Regio- and Stereoselective Cyclization of Chiral Cyclopropenes with Achiral Tethered 
Carbamates
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Stereoselective Cyclization of Prochiral Cyclopropenes with Chiral Enantiomerically Pure 
Carbamates
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Table 1.
Biological Activities of 2,5-Diazabicyclo[5.1.0]octan-6-ones and 2,6-Diazabicyclo[6.1.0]nonan-7-ones
a
compound IC50, μM, HeLa compound IC50, μM, HeLa
8ac 78.0 ± 1.8 8ah 66.2 ± 4.3
8ad >100 8eh 39.0 ± 1.0
8ag >100 8ej 23.7 ± 0.6
8ce >100 8fh 78.1 ± 1.8
8ec 17.4 ± 0.9 8ga >100
a
Concentration required to reduce the viability of cells by 50% after a 48 h treatment with the indicated compounds relative to a DMSO control ± 
SD from two independent experiments, each performed in four replicates, as determined by the MTT assay.
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